Science
Generoath is moving into the future today.
Technology Overview
Overview
- - First-in-class therapeutics with novel target
- - Neurodegeneration-focused pipelines
Gene X coding AAV
- GO-101 : Parkinson`s Disease(PD)
- GO-102 : Amyotrophic Lateral Sclerosis (ALS)
- GO-201 : Retinal Degenerative Disease(RDD)
- Intracranial injection
- Intrathecal injection
- Subretinal/ Intravitreal injection
Features
- Recombinant self-complementary AAV
- Safe profile
- Engineered for expression only at injected site
MOA of GO drugs
- - First-in-class medicine that with novel transgene
- - Fundamental curative mechanism that suppresses neuronal cell apoptosis
- - Stable and long term transgene expression in CNS: lifelong treatment following a single injection
Mode of Action
Our GO series transgene “Gene X”: a powerful and multi-faceted modulator of cell survival and death in neurodegenerative disease.
- Gene A is multi-functional and potent cell death-inducing gene
- Gene X is a splicing variant of Gene A.
- Gene X acts as an antagonistic competitor against Gene A.
- Gene X inhibits Gene A-induced cell death.